[The selection of a drug in a defined therapeutic class: the case of the HMG-CoA reductase inhibitors]

Details

Serval ID
serval:BIB_D5ED7E729C15
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
[The selection of a drug in a defined therapeutic class: the case of the HMG-CoA reductase inhibitors]
Journal
Rev Med Suisse
Author(s)
Girardin F., Desmeules J., Dayer P.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2005
Volume
1
Number
14
Pages
949-53
Language
french
Notes
Girardin, F
Desmeules, J
Dayer, P
fre
English Abstract
Review
Switzerland
Rev Med Suisse. 2005 Apr 6;1(14):949-53.
Abstract
The HMG-CoA reductase inhibitors have similar therapeutic targets and indications. However, their potential pharmacokinetic drug-drug interaction profile may play a significant role in their safety profile in polymedicated and polymorbid patients and can serve as a selection criterion. If their utility is clearly demonstrated in selected conditions, their safety profile remains of concern. Beside dose-related hepatic and muscular injury, other rare and important adverse drug reactions have been reported after prolonged administration such as polyneuropathy, fibrotic interstitial pulmonary disease and lupus-like syndrome. Teratogenicity has also been associated with statin therapy.
Keywords
Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use
Pubmed
Create date
10/02/2021 11:32
Last modification date
11/02/2021 6:26
Usage data